GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland Sells 18,006 Shares

GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) CEO Katherine Stueland sold 18,006 shares of the business's stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $78.18, for a total transaction of $1,407,709.08. Following the completion of the transaction, the chief executive officer now directly owns 53,140 shares of the company's stock, valued at approximately $4,154,485.20. This represents a 25.31 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Katherine Stueland also recently made the following trade(s):

• On Monday, December 16th, Katherine Stueland sold 10,501 shares of GeneDx stock. The stock was sold at an average price of $76.75, for a total value of $805,951.75.
• On Monday, December 9th, Katherine Stueland sold 3,661 shares of GeneDx stock. The stock was sold at an average price of $76.37, for a total transaction of $279,590.57.
• On Monday, November 18th, Katherine Stueland sold 22,307 shares of GeneDx stock. The stock was sold at an average price of $70.34, for a total transaction of $1,569,074.38.
• On Friday, November 15th, Katherine Stueland sold 23,108 shares of GeneDx stock. The stock was sold at an average price of $70.48, for a total value of $1,628,651.84.
• On Tuesday, October 29th, Katherine Stueland sold 2,154 shares of GeneDx stock. The shares were sold at an average price of $66.60, for a total value of $143,456.40.

GeneDx Stock Up 13.2 %

Shares of WGS stock traded up $10.47 during mid-day trading on Monday, reaching $89.61. 1,259,011 shares of the company's stock traded hands, compared to its average volume of 808,279. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25. The company's 50-day moving average price is $76.28 and its 200-day moving average price is $51.22. The company has a market cap of $2.46 billion, a P/E ratio of -28.81 and a beta of 2.03. GeneDx Holdings Corp. has a 12 month low of $2.80 and a 12 month high of $89.66.

GeneDx (NASDAQ:WGS - Get Free Report) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $0.04 EPS for the quarter, topping analysts' consensus estimates of ($0.21) by $0.25. The firm had revenue of $76.90 million for the quarter, compared to analysts' expectations of $64.98 million. GeneDx had a negative return on equity of 13.35% and a negative net margin of 31.25%. The business's revenue for the quarter was up 44.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.82) EPS. On average, equities analysts expect that GeneDx Holdings Corp. will post -0.24 earnings per share for the current fiscal year.

Hedge Funds Weigh In On GeneDx

Several large investors have recently modified their holdings of the stock. Acadian Asset Management LLC bought a new stake in GeneDx during the 2nd quarter valued at about $34,000. CWM LLC purchased a new position in GeneDx in the 3rd quarter worth approximately $89,000. Verition Fund Management LLC lifted its position in GeneDx by 12.9% in the 3rd quarter. Verition Fund Management LLC now owns 25,845 shares of the company's stock valued at $1,097,000 after acquiring an additional 2,945 shares in the last quarter. American Century Companies Inc. boosted its stake in GeneDx by 36.1% during the 2nd quarter. American Century Companies Inc. now owns 17,258 shares of the company's stock valued at $451,000 after purchasing an additional 4,573 shares during the last quarter. Finally, SG Americas Securities LLC bought a new stake in shares of GeneDx in the 3rd quarter worth $198,000. Hedge funds and other institutional investors own 61.72% of the company's stock.

Analyst Ratings Changes

A number of research analysts have commented on WGS shares. Wells Fargo & Company upped their price target on GeneDx from $34.00 to $75.00 and gave the company an "equal weight" rating in a research report on Wednesday, October 30th. Craig Hallum raised their price target on GeneDx from $70.00 to $95.00 and gave the stock a "buy" rating in a research note on Wednesday, October 30th. Finally, The Goldman Sachs Group upped their price objective on shares of GeneDx from $54.00 to $70.00 and gave the stock a "neutral" rating in a report on Wednesday, October 30th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $59.33.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.